Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
Immunocore Holdings (Nasdaq: IMCR) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. PST. The company's management will engage in a fireside chat, which will be webcast live, and available on Immunocore's website. Immunocore specializes in pioneering T cell receptor bispecific immunotherapies, notably its approved oncology therapeutic, KIMMTRAK, intended for treating unresectable or metastatic uveal melanoma. The company is progressing on multiple clinical and pre-clinical programs across various disease areas.
- None.
- None.
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that management will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference.
The presentation is scheduled for Wednesday, January 11, 2023, at 9:00 a.m. Pacific Standard Time (PST).
The presentation will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation will be made available for a limited time.
##
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
CONTACT:
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com
FAQ
When is Immunocore's presentation at the J.P. Morgan Healthcare Conference?
Where can I watch the Immunocore presentation?
What does Immunocore specialize in?
What is KIMMTRAK and its significance?
What type of diseases does Immunocore aim to treat?
